DOCSLIB.ORG

2021 Proxy Statement Creating Tomorrow’S Vaccines Today

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2021 Proxy Statement Creating Tomorrow’S Vaccines Today 2021 proxy statement Creating Tomorrow’s Vaccines Today NOVAVAX FYE 2020 AT A GLANCE Novavax, Inc. (Nasdaq: NVAX), together with our wholly-owned subsidiaries, Novavax AB and $476M revenue Novavax CZ, is a biotechnology company promoting improved global health through the discovery, development and commercialization of innovative $747M invested in R&D vaccines to prevent serious infectious diseases and U.S. patents and pending address urgent, global health needs. 450+ patent applications employees, of which 83% We have more than a decade of experience 691 are engaged in R&D contending with some of the world’s most devastating diseases, including COVID-19, seasonal total sq.ft. in U.S., Swedish, influenza, RSV, Ebola, MERS, and SARS. Hard-won and Czech facilities 438,700 lessons and significant advances illustrate that our proven technology has tremendous potential to make a substantial contribution to public health worldwide. DEVELOPMENT PIPELINE Coronavirus Our vaccine candidates, including both our l NVX-CoV2373 coronavirus vaccine candidate, (“NVX-CoV2373”) l Variant Strain (Booster and/or Bivalent) and our nanoparticle seasonal quadrivalent influenza vaccine candidate (“NanoFluTM” vaccine), Seasonal Influenza are genetically engineered, three-dimensional l TM NanoFlu vaccine (Older Adults) nanostructures of recombinant proteins critical to Combination Vaccines disease pathogenesis. l NanoFlu vaccine/NVX-CoV2373 l NanoFlu vaccine/RSV We are also developing proprietary immune- l NanoFlu vaccine/NVX-CoV2373/RSV stimulating saponin-based adjuvants at Novavax AB, our wholly-owned Swedish subsidiary. Matrix-MTM adjuvant has been shown to enhance immune responses and has been well tolerated in multiple clinical trials. Creating Tomorrow’s Vaccines Today LETTER FROM OUR CEO DEAR NOVAVAX STOCKHOLDER: You are cordially invited to our Annual Meeting of Stockholders on Thursday, June 17, 2021, beginning at 8:30 a.m. Eastern Time. Due to the public health impact of the coronavirus pandemic (“COVID-19”) and to support the health and well-being of our stockholders, this year’s Annual Meeting of Stockholders will be held in a virtual meeting format only. You can virtually attend the live webcast of the Annual Meeting of Stockholders at www.virtualshareholdermeeting.com/NVAX2021. We are pleased to also provide a copy of our 2020 Annual Report to Stockholders with this Proxy Statement. Your vote is important, and we hope you will be able to attend the Annual Meeting. You may vote over the Internet, by telephone, or, if you requested printed proxy materials, by mailing a proxy card or voting instruction form. Please review the instructions for each of your voting options described in this Proxy Statement. Also, please let us know if you plan to attend the live virtual webcast of our Annual Meeting by marking the appropriate box on the proxy card, if you requested printed proxy materials, or, if you vote by telephone or over the Internet, by indicating your plans when prompted. We look forward to seeing you at our 2021 Annual Meeting. Yours truly, STANLEY C. ERCK At Novavax, our dedication to our President and Chief Executive Officer mission necessitates that we May 3, 2021 focus efforts on a vaccine that can help global health authorities address, control, and potentially eradicate SARS-CoV-2, the virus responsible for COVID-19. We are seeking to fulfill our mission with NVX-CoV2373. Creating Tomorrow’s Vaccines Today NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON THURSDAY, JUNE 17, 2021 TO THE STOCKHOLDERS OF NOVAVAX, INC.: NOTICE IS HEREBY GIVEN that the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Novavax, Inc., a Delaware corporation (the “Company,” “Novavax,” “we,” or “us”), will be held: WHEN VIRTUAL WEBCAST RECORD DATE Thursday, June 17, 2021 www.virtualshareholdermeeting. Stockholders of record at the close 8:30 a.m. Eastern Time com/NVAX2021 of business on April 20, 2021 are entitled to notice of and to vote Matters to Be Voted on at the Annual Meeting Proposal 1 Election of three directors as Class II directors to serve on the board of directors, each for a three-year term expiring at the 2024 Annual Meeting of Stockholders Advisory vote to approve the compensation of our Named Executive Officers 2 3 Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the “2015 Stock Plan”) to increase the number of shares of the Company’s common stock, par value $0.01 (our “Common Stock”), available for issuance thereunder by 1,500,000 shares Ratification of certain April 2020 equity awards 4 5 Ratification of certain June 2020 equity awards 6 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021 7 Transaction of such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof The board of directors has fixed the close of business on April 20, 2021 (the “Record Date”) as the record date for determining stockholders of the Company entitled to notice of and to vote at the Annual Meeting and any adjournments or postponements thereof. The following Proxy Statement is included with the Company’s Annual Report to Stockholders for the fiscal year ended December 31, 2020, which contains financial statements and other information of interest to stockholders. By Order of the Board of Directors, JOHN A. HERRMANN III Executive Vice President, Chief Legal Officer and Corporate Secretary Gaithersburg, Maryland May 3, 2021 Whether or not you plan to attend the virtual webcast IMPORTANT NOTICE REGARDING THE AVAILABILITY of the annual meeting, please promptly vote over the OF PROXY MATERIALS FOR THE STOCKHOLDERS Internet or by telephone as per the instructions on the ANNUAL MEETING TO BE HELD ON JUNE 17, 2021 enclosed proxy or complete, sign and date the enclosed proxy and mail it promptly in the accompanying Our Notice of Annual Meeting, Proxy Statement, and envelope. Postage is not needed if mailed in the United Annual Report are available free of charge at States. www.virtualshareholdermeeting.com/NVAX2021 PROXY STATEMENT Table of Contents 1 Proxy Summary 51 Potential Payments Upon Termination 53 2020 CEO Pay Ratio 7 Board of Directors and Corporate 54 Proposal 3—Amendment and Restatement of Governance the 2015 Stock Plan 7 Proposal 1—Election of Directors 64 Proposal 4—Ratification of Certain April 2020 7 Nominees for Election as Class II Directors Equity Awards 9 Directors Continuing as Class III Directors 64 Proposal 5—Ratification of Certain June 2020 Equity Awards 11 Directors Continuing as Class I Directors 12 Information Regarding the Board and Corporate Governance Matters 72 Audit Matters 13 Leadership Structure and Risk Oversight 72 Proposal 6—Ratification of the Appointment of Ernst & Young LLP as the Company’s 15 Board Committees Independent Registered Public Accounting 19 Nomination Procedures Firm for the Fiscal Year Ending December 31, 21 Corporate Governance Guidelines 2021 21 Code of Business Conduct and Ethics 72 Fees and Services 22 Stockholder Communications with the Board of 73 Audit Committee Pre-Approval Policies and Directors Procedures 22 Certain Relationships and Related Transactions 74 Audit Committee Report 22 Compensation Committee Interlocks and Insider Participation 75 Stock Ownership Information 23 Compensation of Directors 75 Security Ownership of Certain Beneficial Owners and Management 26 Executive Officers and Compensation 26 Proposal 2—Advisory Vote on Executive 77 Information about the Annual Meeting and Compensation (Say-on-Pay) Voting 27 Executive Officers 30 Compensation Discussion and Analysis 82 Additional Information 42 Compensation Committee Report 82 Stockholder Proposals 43 Executive Compensation Tables 83 Other Matters 43 Summary Compensation Table 44 Grants of Plan-Based Awards Table A-1 Appendix A—Novavax, Inc. Amended and Restated 2015 Stock Plan 46 Outstanding Equity Awards at 2020 Fiscal Year End 48 Options Exercised and Stock Appreciation Rights B-1 Appendix B—Stockholder Complaint Exercised and Stock Vested 48 Overview of Employment and Change in Control Agreements PROXY SUMMARY This summary represents only selected information. You should review the entire proxy statement before voting. Novavax, Inc. 2021 Annual Meeting of Stockholders WHEN VIRTUAL WEBCAST RECORD DATE Thursday, June 17, 2021 www.virtualshareholdermeeting. Stockholders of record at the close 8:30 a.m. Eastern Time com/NVAX2021 of business on April 20, 2021 are entitled to notice of and to vote MATTERS TO BE VOTED ON AT THE ANNUAL MEETING Proposal Board Recommendation See Page Election of three directors as Class II directors to serve on the board of FOR 7 1 directors, each for a three-year term expiring at the 2024 Annual Meeting of all nominees Stockholders Advisory vote to approve the compensation of our Named Executive Officers FOR 26 2 3 Amendment and restatement of the Novavax, Inc. 2015 Stock Plan to FOR 54 increase the number of shares of Common Stock available for issuance thereunder by 1,500,000 shares Ratification of certain April 2020 equity awards FOR 64 4 Ratification of certain June 2020 equity awards FOR 64 5 Ratification of the appointment of Ernst & Young LLP as our independent 6 72 registered public accounting firm for the fiscal year ending December 31, FOR 2021 7 Transaction of such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof NOVAVAX, INC. 2021 PROXY STATEMENT
Load more

Recommended publications
  • Preparedness: Responding to Biological Attacks, Pandemics, and Emerging Infec- Tious Disease Outbreaks
    THE STATE OF U.S. PUBLIC HEALTH BIO- PREPAREDNESS: RESPONDING TO BIOLOGICAL ATTACKS, PANDEMICS, AND EMERGING INFEC- TIOUS DISEASE OUTBREAKS HEARING BEFORE THE SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED FIFTEENTH CONGRESS SECOND SESSION FRIDAY, JUNE 15, 2018 Serial No. 115–140 ( Printed for the use of the Committee on Energy and Commerce energycommerce.house.gov U.S. GOVERNMENT PUBLISHING OFFICE 35–127 WASHINGTON : 2019 VerDate Nov 24 2008 13:47 Feb 28, 2019 Jkt 037690 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 U:\MY DOCS\HEARINGS 115\HEARINGS\115-140 CHRIS COMMITTEE ON ENERGY AND COMMERCE GREG WALDEN, Oregon Chairman JOE BARTON, Texas FRANK PALLONE, JR., New Jersey Vice Chairman Ranking Member FRED UPTON, Michigan BOBBY L. RUSH, Illinois JOHN SHIMKUS, Illinois ANNA G. ESHOO, California MICHAEL C. BURGESS, Texas ELIOT L. ENGEL, New York MARSHA BLACKBURN, Tennessee GENE GREEN, Texas STEVE SCALISE, Louisiana DIANA DEGETTE, Colorado ROBERT E. LATTA, Ohio MICHAEL F. DOYLE, Pennsylvania CATHY MCMORRIS RODGERS, Washington JANICE D. SCHAKOWSKY, Illinois GREGG HARPER, Mississippi G.K. BUTTERFIELD, North Carolina LEONARD LANCE, New Jersey DORIS O. MATSUI, California BRETT GUTHRIE, Kentucky KATHY CASTOR, Florida PETE OLSON, Texas JOHN P. SARBANES, Maryland DAVID B. MCKINLEY, West Virginia JERRY MCNERNEY, California ADAM KINZINGER, Illinois PETER WELCH, Vermont H. MORGAN GRIFFITH, Virginia BEN RAY LUJA´ N, New Mexico GUS M. BILIRAKIS, Florida PAUL TONKO, New York BILL JOHNSON, Ohio YVETTE D. CLARKE, New York BILLY LONG, Missouri DAVID LOEBSACK, Iowa LARRY BUCSHON, Indiana KURT SCHRADER, Oregon BILL FLORES, Texas JOSEPH P.
    [Show full text]
  • Biden-Harris Transition Announces COVID-19 Advisory Board
    BIDEN-HARRIS TRANSITION The President-Elect The Vice President-Elect Priorities Transition Español NOVEMBER 09, 2020 PRESS RELEASES Biden-Harris Transition Announces COVID-19 Advisory Board Leading Public Health and Scientific Experts to Advise the Transition on COVID-19 Response WASHINGTON – Today, the Biden-Harris Transition announced the formation of the Transition COVID-19 Advisory Board, a team of leading public health experts who will advise President-elect Biden, Vice President-elect Harris, and the Transition’s COVID-19 staff. The Transition COVID-19 Advisory Board will be led by co-chairs Dr. David Kessler, Dr. Vivek Murthy, and Dr. Marcella Nunez-Smith. Dr. Beth Cameron and Dr. Rebecca Katz are serving as advisors to the Transition on COVID-19 and will work closely with the Advisory Board. “Dealing with the coronavirus pandemic is one of the most important battles our administration will face, and I will be informed by science and by experts,” said President-elect Biden. “The advisory board will help shape my approach to managing the surge in reported infections; ensuring vaccines are safe, effective, and distributed efficiently, equitably, and free; and protecting at-risk populations.” New cases are rising in at least 40 states, with more than 9.3 million total infections and more than 236,000 deaths. President-elect Biden has pledged to bring leadership to the COVID pandemic, which continues to claim thousands of lives each week, by curbing the spread of the disease, providing free treatment to those in need, and elevating the voices of scientists and public health experts. The COVID-19 Advisory Board will help guide the Biden-Harris Transition in planning for the President-elect’s robust federal response.
    [Show full text]
  • Bio's Virtual Summit Advances Medical Countermeasure
    BIO’S VIRTUAL SUMMIT ADVANCES MEDICAL COUNTERMEASURE PARTNERSHIPS FOR COVID-19 Launches Ongoing Initiative to Accelerate and Coordinate Development of Drugs, Vaccines, Preventives, and Diagnostics On March 24-25, 2020, BIO virtually convened more than 500 leaders from across industry, government, academia, and NGOs to assess the state of the pandemic and accelerate medical countermeasure solutions for COVID-19. BIO CEO Jim Greenwood and Dr. George Scangos, CEO of Vir, hosted the two-day summit to identify pressing technical, funding, regulatory and policy challenges, and enable BIO to catalyze cross- industry collaborations and public-private partnerships to advance development of medical countermeasures. Participants heard from key government officials, including Ambassador Deborah Birx, White House Coronavirus Response Coordinator, Dr. Robert Kadlec, HHS Assistant Secretary for Preparedness and Response, and Dr. Rick Bright, Director, Biomedical Advanced Research and Development Authority. KEY FINDINGS Based on Summit discussion, BIO identified the following critical needs and concerns: Successful development efforts will require the federal government to facilitate sharing of all relevant scientific and epidemiologic data and information as quickly and efficiently as possible. Many promising solutions will emerge from small and mid-sized companies and research laboratories, but these entities will likely have difficulty navigating the complex government contracting and regulatory bureaucracy; real-time assistance is needed. Early and rapid decisions from government funders will be essential to support immediate research, development, and clinical trial activity in order to identify the most promising candidates for further R&D and collaboration. Regulatory, advisory, and reimbursement authorities must be involved with requirement-setting and decision-making early on to prevent bottlenecks and downstream delays.
    [Show full text]
  • Key Global Health Positions and Officials in the U.S. Government
    January 2019 | Fact Sheet Key Global Health Positions and Officials in the U.S. Government Position Official WHITE HOUSE/EXECUTIVE OFFICE OF THE PRESIDENT Assistant to the President for National Security Affairs/National Security Advisor, National Security John Bolton Council (NSC) Senior Director for Weapons of Mass Destruction and Biodefense, NSC Tim Morrison Director for Medical and Biodefense Preparedness Policy, NSC Luciana Borio Director for Countering Biological Threats, NSC Hillary Carter Director for Global Health and International Development, NSC Peter Mamacos Special Assistant to the President; Senior Director for International Organizations and Alliances, Erin Walsh NSC Director, Office of Management and Budget (OMB) Mick Mulvaney Associate Director for National Security Programs, OMB Robert Blair Deputy Associate Director, International Affairs Division, National Security Programs, OMB Robert Fairweather Chief, Economic Affairs Branch, International Affairs Division, National Security Programs, OMB Fouad Saad Program Examiner, International Affairs Division, National Security Programs, OMB Will Cole Associate Director, Health Programs, OMB Joe Grogan Deputy Associate Director, Health Division, Health Programs, OMB Tom Reilly Chief, Public Health Branch, Health Programs, OMB Marc Garufi Program Examiner, Public Health Branch, Health Programs, OMB Nicholas Burton U.S. Trade Representative, Office of the United States Trade Representative (USTR) Robert Lighthizer Deputy U.S. Trade Representative, USTR C.J. Mahoney Assistant
    [Show full text]
  • Coalition for Epidemic Preparedness Innovations New Vaccines for a Safer World
    Coalition for Epidemic Preparedness Innovations New vaccines for a safer world Frederik Kristensen DCVMN Annual Meeting 25 October 2016 FOUNDING PARTNERS The challenge of epidemics Calls for global action CEPI - January - June Task Team Interim CEO High Level Task Team Leadership Meeting, Oslo appointed Meeting Tele- Group Meeting 6-7 April and constituted Davos conferences Washington DC Business Plan 21 January 17 May presented to stakeholders CEPI - July - September UNGA side Core Group First CEPI G7 Health event on health and CEPI soft interim board ministers’ side emergencies, Leadership launch meeting event, NY, Group Tele- Media London, Kobe, 19 September conferences coverage 31 August 10 September Challenges The pipeline is weak for most emerging infectious 1 diseases characterized by lack of market incentives Unilateral, uncoordinated government efforts to 2 fund R&D preparedness are inefficient and unsustainable in addressing global epidemic risks Clinical & regulatory pathways are not easily 3 adaptable to epidemic contexts Incentives are lacking to motivate 4 greater industry engagement Vaccine pipelines 45 40 35 30 25 20 15 10 5 0 Academic Government agency Biotech MNC Non-profits Preclinical Phase I Phase II Phase II/III Phase III Opportunities The Ebola momentum: vaccines are a feasible strategy, 1 despite a risky development pathway The Ebola momentum: it is possible to advance the 2 clinical development of safe and effective vaccines against EIDs in an emergency R&D actors supporting EID vaccine pipelines: 3 government health research agencies, academic research institutions, biotechs, vaccine manufacturers, and non-profits Manufacturing capability and capacity for vaccines has 4 always been a critical bottle-neck in epidemic events.
    [Show full text]
  • OP Ed: Another Victim of the Coronavirus: TRUTH (And a Not-To-Forget Lesson for People in Our Business)
    OP Ed: Another Victim Of The Coronavirus: TRUTH (And a Not-To-Forget Lesson For People In Our Business) Arthur Solomon, Public Relations Consultant The deadly coronavirus hates people. It has separated people from their families. It has separated people from their friends. It has caused massive unemployment. It frightens people. It is also responsible for an increase in hate messages on social media, targeting all minority populations, ranging from African-Americans, to Asian-Americans to religious Americans who practice Orthodox Judaism and to Jews who don’t. It has destroyed our way of living. The virus makes people very ill. Worst of all it kills people. But there is also a victim that was only made possible with the assistance of humans – TRUTH. President Trump’s revisionist remarks about the coronavirus, which is happening as I write this, on April 26, continues. The result: For many Americans is there is no TRUTH. And politics and the media have played a large part in aiding the virus to put TRUTH on life support. While TRUTH had been ill since January, it took a sudden turn for the worse in the U.S. on February 28, during a rally in South Carolina, when President Trump described the virus as a Democratic “hoax.” Other presidential remarks like saying, anyone who wants a test can get one; there are plenty of PPE supplies; doctors and nurses are hording them; we have the situation under control; his hawking of medicines for people infected with the disease as if he was a medical scientist, and his contradictory remarks about blaming the coronavirus on China, to name a few of the president’s comments, all added to put TRUTH in a grave condition.
    [Show full text]
  • AKDN COVID-19 Policy Digest Bulletin #33 | Date: 16 November 2020 International Scientific Brief: Community Use of Cloth Mask
    1 AKDN COVID-19 Policy Digest Bulletin #33 | Date: 16 November 2020 International Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2 Centers for Disease Control and Prevention (CDC) https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html In a brief published on 10 November, the CDC recommends community use of masks, specifically non- valved multi-layer cloth masks, to prevent transmission of SARS-CoV-2. Masks are primarily intended to reduce the emission of virus-laden droplets (source control), which is especially relevant for asymptomatic or presymptomatic infected wearers who feel well and may be unaware of their infectiousness to others, and who are estimated to account for more than 50% of transmissions. Masks also help reduce inhalation of these droplets by the wearer (“filtration for personal protection”). The Johns Hopkins Center for Health Security explains that this guidance is noteworthy because masks can provide protection for the wearer as well, including the ability to filter “fine droplets and particles less than 10 micros.” Recent studies found that the filtration effect varied between masks and mask types, with multi-layer masks and mask types constructed with more densely woven material, preforming better than single-later masks made from lower thread count fabric. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 U.S. Food and Drug Administration (FDA) https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes- monoclonal-antibody-treatment-covid-19 The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on 9 November, for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and paediatric patients.
    [Show full text]
  • COVID 19 Review Monografia N
    COVID 19 Review Monografia n. 5 Covid19 e i vaccini: i piani vaccinali e la logistica. A cura di Giorgio Banchieri, Antonio Giulio De Belvis, Maurizio Dal Maso, Lidia Goldoni, Stefania Mariantoni, Mario Ronchetti, Andrea Vannucci. Review realizzata in collaborazione con : 1 Nota redazionale. I materiali (articoli e dati) vengono selezionati da fonti accreditate: . Per gli articoli: The Lancet, British Medicine Journal, The New York Times, Science, Nature, Oxford Review, Cambridge Review, Quotidiano Sanità, Il Corriere della Sera, Il Sole 24Ore Sanità, La Repubblica e altri; Per le Istituzioni: . WH0/OMS, UE Centri di Prevenzione; OCDE, ONU, Protezione Civile, ISTAT, INAIL, Ministero Salute, ISS, AGENAS, CNR, Regioni, ARS, ASL, AO, AOP, IRCCS, Centri Studi e ricerche nazionali e internazionali e altri; Per i dati: . WH0/OMS, UE Centri di Prevenzione; OCDE, ONU, Protezione Civile, ISTAT, INAIL, Ministero Salute, ISS, AGENAS, CNR, Regioni, ARS, ASL, AO, AOP, IRCCS, Centri Studi e ricerche nazionali e internazionali e altri; Criteri di selezione: I materiali sono scelti in base ai seguenti criteri: Materiali di analisi recenti; Fonti accreditate; Tematiche inerenti a COVID19; Procedure internazionali e nazionali; Studi e ricerche epidemiologici; Studi su procedure per operatori sanitari e sociali; Linee Guida internazionali, nazionali e regionali; Linee Guida di società scientifiche e professionali. Le traduzioni sono fatte in automatico con il software “google” per rapidità di fruizione. Ci scusiamo se le traduzioni non sono sempre adeguate, ma riteniamo più utile la tempestività di divulgazione. Si ringraziano l’Editore COM SRL di Roma per il supporto Si ringrazia la Dr.ssa Giulia D’Allestro per il database repository.
    [Show full text]
  • Dr. Rick Bright, One of the Nation's Leading Experts in Pandemic
    THIRD ADDENDUM TO THE COMPLAINT OF PROHIBITED PERSONNEL PRACTICE AND OTHER PROHIBITED ACTIVITY BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBMITTED BY DR. RICK BRIGHT I. Introduction Dr. Rick Bright, one of the nation’s leading experts in pandemic preparedness and response, and an internationally recognized expert in the fields of immunology, therapeutic intervention, and vaccine and diagnostic development, was abruptly removed from his position as Director of the Biomedical Advanced Research and Development Authority (“BARDA”) and transferred to a limited position at the National Institutes of Health (“NIH”) in retaliation for his whistleblowing activity under 5 U.S.C. § 2302(b)(8)(A). Specifically, and as detailed in his initial Complaint of Prohibited Personnel Practice filed with the Office of Special Counsel (“OSC”) on May 5, 2020, Secretary of Health and Human Services, Alex Azar, and other HHS political leaders engaged in an overtly hostile and career-derailing campaign of retaliation against Dr. Bright because he raised concerns about the Trump administration’s chaotic and reckless response to the COVID-19 pandemic. Shortly after cases of COVID-19 were identified in the United States, Dr. Bright sounded the alarm about the shortage of critical supplies, such as masks, respirators, swabs, and syringes that were necessary to combat COVID-19. In response, HHS political leadership leveled baseless criticisms against him and sidelined him because of his insistence that the Trump administration address these shortages and invest in vaccine development as well. Dr. Bright continued to speak out about the inevitable devastation that would be wrought by this virus at a time President Trump and his administration were intentionally lying to the American people about the serious threat posed by COVID-19 to the public health and safety.1 Dr.
    [Show full text]
  • Last Week, Rick Bright, the Former Director of the Biomedical Advanced Research and Development Authority (BARDA), Filed a Whistleblower Complaint with the U.S
    What the Bright Complaint Reveals about the Trump Administration’s COVID-19 Response Last week, Rick Bright, the former director of the Biomedical Advanced Research and Development Authority (BARDA), filed a whistleblower complaint with the U.S. Office of Special Counsel. Dr. Bright claims he was forced out from his role because he “insisted on scientifically-vetted proposals” and “pushed for a more aggressive agency response to COVID-19.” His allegations are shocking. Even in an Administration characterized by cronyism and incompetence, the failure of HHS political leadership to respond to COVID- 19 stands out. The Office of Special Counsel has already found “reasonable grounds to believe” that the Administration retaliated against Dr. Bright, and recommended that his removal be stayed while it investigates.1 His supervisor Robert Kadlec, the assistant secretary for preparedness and response (ASPR) at the Department of Health and Human Services, must step down. Given the multiple claims of political interference in the contracting process, HHS should fully disclose the terms of all contracts issued under Dr. Kadlec, and all evidence used to support contract awards. I. The Trump Administration Ignored Requests by Career Officials to Prepare for COVID-19. As early as January 10, 2020, Dr. Bright was urging HHS to dedicate appropriate resources to COVID-19. In response, “HHS political leadership leveled baseless criticisms against him for his proactive efforts to invest early in vaccine development as well as in critical supplies such as masks, respirators, and swabs, which were in short supply and would be necessary to combat COVID-19.”2 A Lack of Urgency: On January 18, Dr.
    [Show full text]
  • 73261 RA 2019Forum Program.Indd
    NATIONAL HEALTH RESEARCH FORUM STRAIGHT TALK NEW THINKING ON PERSISTENT CHALLENGES LEAD SPONSOR Pfizer PANEL SPONSORS AAMC AdvaMed BD September 5, 2019 Elsevier 9:00 a.m. to 2:45 p.m. Johnson & Johnson Innovation Patient-Centered Outcomes CONRAD WASHINGTON, DC Research Institute (PCORI) Regeneron Sanofi #RAFORUM19 Takeda Pharmaceutical Company Limited The Research!America Board of Directors thanks the Lead Sponsor: The Research!America Board of Directors thanks the Panel Sponsors: NATIONAL HEALTH RESEARCH FORUM STRAIGHT TALK NEW THINKING ON PERSISTENT CHALLENGES Breakfast Speaker Robert R. Redfield, MD Director, Centers for Disease Control and Prevention Administrator, Agency for Toxic Substances and Disease Registry Robert R. Redfield, MD, is the 18th director of the Centers for Disease Control and Prevention and administrator of the Agency for Toxic Substances and Disease Registry. He has been a public health leader actively engaged in clinical research and clinical care of chronic human viral infections and infectious diseases, especially HIV, for more than 30 years. He served as the founding director of the Department of Retroviral Research within the U.S. Military’s HIV Research Program, and retired after 20 years of service in the U.S. Army Medical Corps. He is a past member of the Office of AIDS Research Advisory Council at the National Institutes of Health, the Fogarty International Center Advisory Board at the National Institutes of Health, and the Advisory Anti-Infective Agent Committee of the Food and Drug Administration. * as of August 27, 2019 NEW THINKING ON PERSISTENT CHALLENGES 1 PANEL 1 Margaret (Peggy) Hamburg, MD Women Researchers Leading Discovery Foreign Secretary, National Academy of Medicine Dr.
    [Show full text]
  • Mcmx: a Proposal for a Federal Authority to Enhance Speed, Scale and Access to Medical Countermeasures
    MCMx: A Proposal for a Federal Authority to Enhance Speed, Scale and Access to Medical Countermeasures Findings from the Program in Global Public Policy and Social Change Medical Countermeasures Taskforce: Partnering for Public Good Authors Kendall Hoyt, Geisel School of Medicine, Dartmouth College Margaret Bourdeaux, Harvard Medical School Annmarie Sasdi, Harvard Medical School May 28, 2021 PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE TASK FORCE MEMBERS Katrine Thor Andersen Deputy Director, Global Health, William and Melinda Gates Foundation Thomas J. Bollyky Director, Global Health Program, Council on Foreign Relations Rick Bright, PhD Senior Vice President, Pandemic Prevention & Response, Health Initiative, The Rockefeller Foundation Philip Dormitzer, MD, PhD Vice President and Chief Scientific Officer Viral Vaccines, Pfizer Rebecca Fish President, Hart Ledge Consulting Bruce Gellin, MD, MPH President, Global Immunization, Sabin Vaccine Institute Arpa (Shah) Garay President, Global Pharmaceuticals, Commercial Analytics, Digital Marketing, Merck & Co. Jonathan P. Gertler, MD Managing Partner and CEO Of Back Bay Life Science Advisors and Managing Director, Bioventures Investors Medtech Funds Robert V. House, PhD, FATS Senior Vice President, Government Contracts, Ology Bioservices Kendall Hoyt, PhD Assistant Professor, Geisel School of Medicine, Dartmouth College Heather Ignatius Director, U.S. and Global Policy and Advocacy, PATH Ryan Morhard Ginkgo Bioworks Jake Reder, PhD CEO, Celdara Medical James Robinson Vice Chair, The Coalition for Epidemic Preparedness Innovations Julia Barnes-Weise, J.D., CFP Executive Director, The Global Healthcare Innovation Alliance Accelerator (GHIAA) Charlie Weller Head of Vaccines, Wellcome Trust 2 PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE CONTENTS I. Introduction II. MCMx Mission III. MCMx Strategic Plan: Creating a Research and Development Blueprint for MCMs in Future Outbreaks A.
    [Show full text]